- Home
- NTLA vs SVM Comparison
NTLA vs SVM Comparison
Compare NTLA & SVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- SVM
- Stock Information
- Founded
- NTLA 2014
- SVM N/A
- Country
- NTLA United States
- SVM Canada
- Employees
- NTLA N/A
- SVM N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SVM Precious Metals
- Sector
- NTLA Health Care
- SVM Basic Materials
- Exchange
- NTLA Nasdaq
- SVM Nasdaq
- Market Cap
- NTLA 1.2B
- SVM 1.1B
- IPO Year
- NTLA 2016
- SVM N/A
- Fundamental
- Price
- NTLA $10.90
- SVM $4.56
- Analyst Decision
- NTLA Buy
- SVM Strong Buy
- Analyst Count
- NTLA 20
- SVM 1
- Target Price
- NTLA $32.30
- SVM $6.75
- AVG Volume (30 Days)
- NTLA 5.0M
- SVM 4.5M
- Earning Date
- NTLA 08-07-2025
- SVM 08-07-2025
- Dividend Yield
- NTLA N/A
- SVM 0.55%
- EPS Growth
- NTLA N/A
- SVM N/A
- EPS
- NTLA N/A
- SVM 0.25
- Revenue
- NTLA $52,857,000.00
- SVM $308,064,000.00
- Revenue This Year
- NTLA N/A
- SVM $8.43
- Revenue Next Year
- NTLA N/A
- SVM $27.40
- P/E Ratio
- NTLA N/A
- SVM $18.20
- Revenue Growth
- NTLA 14.99
- SVM 35.50
- 52 Week Low
- NTLA $5.90
- SVM $2.87
- 52 Week High
- NTLA $24.16
- SVM $5.32
- Technical
- Relative Strength Index (RSI)
- NTLA 45.06
- SVM 50.28
- Support Level
- NTLA $10.57
- SVM $4.30
- Resistance Level
- NTLA $11.51
- SVM $4.67
- Average True Range (ATR)
- NTLA 0.69
- SVM 0.18
- MACD
- NTLA -0.26
- SVM -0.02
- Stochastic Oscillator
- NTLA 10.44
- SVM 52.63
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.